Nuveen
NGNE icon

Nuveen’s Neurogene NGNE Stock Holding History

Nuveen’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$875K Buy
27,824
+2,614
+10% +$72K ﹤0.01% 3000
2026
Q1 		$508K Buy
25,210
+4,117
+20% +$79.7K ﹤0.01% 2829
2025
Q4 		$435K Hold
21,093
– – ﹤0.01% 2922
2025
Q3 		$366K Sell
21,093
-1,574
-7% -$31.6K ﹤0.01% 2997
2025
Q2 		$339K Sell
22,667
-4,815
-18% -$75.6K ﹤0.01% 3001
2025
Q1 		$322K Hold
27,482
– – ﹤0.01% 3018
2024
Q4 		$628K Hold
27,482
– – ﹤0.01% 2902
2024
Q3 		$1.15M Hold
27,482
– – ﹤0.01% 2693
2024
Q2 		$1M Buy
+27,482
New +$969K ﹤0.01% 2729
2022
Q2 		– Sell
-6,533
Closed -$252K – 3411
2022
Q1 		$252K Buy
6,533
+74
+1% +$4.32K ﹤0.01% 3150
2021
Q4 		$614K Sell
6,459
-547
-8% -$66.6K ﹤0.01% 3013
2021
Q3 		$1.16M Sell
7,006
-32
-0.5% -$4.9K ﹤0.01% 2940
2021
Q2 		$1.3M Sell
7,038
-56
-0.8% -$12.4K ﹤0.01% 2902
2021
Q1 		$1.75M Sell
7,094
-7,948
-53% -$2.03M ﹤0.01% 2681
2020
Q4 		$4.24M Sell
15,042
-269
-2% -$65.7K ﹤0.01% 2160
2020
Q3 		$3.67M Buy
15,311
+4,896
+47% +$1.19M ﹤0.01% 2079
2020
Q2 		$3.46M Buy
+10,415
New +$2.71M ﹤0.01% 2088

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Nuveen's NGNE Position: Q2 2026 in Review

Nuveen increased its Neurogene (NGNE) stake by 10% in Q2 2026, buying an estimated $72K and bringing the position to 27,824 shares worth $875K. The position accounts for ﹤0.01% of the portfolio, ranked #3000.

Nuveen first reported a position in NGNE in Q2 2020 and has held it in 17 quarters since. The position peaked at $4.24M in Q4 2020. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Nuveen held 27,824 shares of Neurogene worth $875K as of Q2 2026.
  • Nuveen bought 2,614 Neurogene shares in Q2 2026, an estimated $72K.
  • Neurogene made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3000 holding.
  • Nuveen first reported a position in Neurogene in Q2 2020 and has held it in 17 quarters since.
  • Nuveen's Neurogene position peaked at $4.24M in Q4 2020.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.